Evaxion Biotech A/S (NASDAQ:EVAX) shares traded -1.97% lower at $1.74 on Wall Street last session.
In accordance with the data, 3 analysts cover Evaxion Biotech A/S (NASDAQ:EVAX). The consensus rating among analysts is ‘Buy’. EVAX stock price is now -21.07% away from the 50-day moving average and -28.13% away from the 200-day moving average. The market capitalization of the company currently stands at $41.27M.
It has been rated a hold by 0 analysts and a buy by 3.
A total of 42.47% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EVAX stock. In total, there are 13 active investors with 1.60% ownership of the company’s stock.
Evaxion Biotech A/S (NASDAQ: EVAX) opened at $2.0900 on Tuesday. During the past 12 months, Evaxion Biotech A/S has had a low of $1.51 and a high of $4.67. As of last week, the company has a debt-to-equity ratio of 0.48, a current ratio of 6.50, and a quick ratio of 6.50. The fifty day moving average price for EVAX is $2.2044 and a two-hundred day moving average price translates $2.4211 for the stock.
The latest earnings results from Evaxion Biotech A/S (NASDAQ: EVAX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.2, beating analysts’ expectations of -$0.3 by 0.1. This compares to -$0.27 EPS in the same period last year. The company reported revenue of $6.08 million for the quarter, compared to $5.91 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.89 percent.
Evaxion Biotech A/S(EVAX) Company Profile
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.